Last edition
News about " TOGETHER-PsO clinical trial "
Eli Lilly Reports Biomarker Changes With Taltz-Zepbound Combination
Eli Lilly has reported broader immune, inflammatory and metabolic biomarker changes with Taltz and Zepbound compared with Taltz alone in the TOGETHER-PsO trial.
TOGETHER-PsO Clinical Trial | 12/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members